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Background. A5350, a phase II, randomized, double-blind study, evaluated the safety and tolerability of the probiotic Visbiome
Extra Strength (ES) over 24 weeks and measured effects on inflammation and intestinal barrier function.
Methods. The primary outcome was change in soluble CD14 (sCD14) levels; secondary outcomes included safety and tolerability, markers of inflammation and cellular activation, and microbiome. In a substudy, gut permeability was assessed by paired colonic biopsies measuring the area of lamina propria occupied by CD4+ cells, interleukin (IL)-17+ cells, and myeloperoxidase (MPO).
Changes between arms were compared with the 2-sample t test with equal variance or the Wilcoxon rank-sum test. For safety, the
highest graded adverse events (AEs) were compared between arms using the Fisher exact test.
Results. Overall, 93 participants enrolled: 86% male, median age 51 years, median CD4 count 712 cells/mm3. Visbiome ES
was safe and well tolerated. There was no difference in mean change in sCD14 from baseline to week 25/26 between placebo (mean
change, 92.3 µg/L; 95% CI, –48.5 to 233 µg/L) and Visbiome ES (mean change, 41.0 µg/L; 95% CI, –94.1 to 176.2 µg/L; P = .60).
Similarly, no statistically significant differences between arms in inflammatory marker changes were identified. In substudy participants, no statistical differences between arms for change in cellular marker expression or gut permeability were observed (P > .05
for all). The microbiome demonstrated increased probiotic species and a significant decrease in Gammaproteobacteria (P = .044) in
the Visbiome ES arm.
Conclusions. Visbiome ES was safe and altered the microbiome but demonstrated no effect on systemic inflammatory markers,
pathology, or gut permeability in antiretroviral therapy–treated people with HIV.
Keywords. HIV; human microbiome; inflammation; probiotics.
HIV infection confers a chronic inflammatory state, impairing
immune function and exacerbating chronic disease risk. HIVrelated alterations in the intestinal microbiome are associated
with CD4+ T-cell depletion and chronic inflammation [1–4].
Previous studies have found that gut microbiota and related
metabolites, including tryptophan metabolism, are altered in
people with HIV (PWH) [1, 2, 5, 6]. HIV infection of intestinal CD4+ T cells results in intestinal epithelial damage, with
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decreased colonic epithelial tight junction proteins and increased colonic permeability, and facilitates microbial translocation despite suppressive antiretroviral therapy (ART) [7]. As
systemic inflammation has been linked with long-term morbidity and mortality [8], adjunctive interventions are needed to
improve gut integrity.
Probiotics are organisms such as yeast or bacteria available
in foods and supplements that may improve overall gut health
and reduce excess intestinal permeability [9, 10]. Various probiotics have been studied in disease states associated with gastrointestinal dysbiosis, including inflammatory bowel disease
(IBD) and infectious diarrhea. In addition to intestinal health,
probiotic bacteria may have effects on immune function and
response to infection or vaccination [11]. This has been most
clearly demonstrated in the case of diarrheal illness, such as
Clostridioides difficile disease [12–14].
The promising effects of probiotics on gut dysbiosis and inflammation have been described in simian immunodeficiency
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A Randomized, Placebo-Controlled Trial Assessing the
Effect of VISBIOME ES Probiotic in People With HIV on
Antiretroviral Therapy

METHODS
Study Participants and Design

PWH at AIDS Clinical Trials Group sites in the United States,
age >18 years, on stable ART, with CD4+ T-cell count >200
cells/mm3 were eligible. History of inflammatory bowel disease,
total colectomy, or chronic liver disease; recent or current use
of antimicrobials, immunomodulatory or probiotic treatment
(including probiotic yogurt), or active substance abuse interfering with study procedures were exclusionary. Participants
were randomized 1:1 to Visbiome ES or placebo for 24 weeks
starting at week 2 and followed for an additional 12 weeks off
study product.
Patient Consent

Written informed consent was obtained from all participants
before participation, and the human experimentation guidelines of the US Department of Health and Human Services
were followed. The study was approved by institutional review
boards at all participating sites (NCT02706717).
Collections

Blood samples were collected to measure markers of cellular
activation, inflammation, gut damage, and bacterial translocation. Plasma concentrations of sCD14 were quantified
using the human sCD14 enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems) per the manufacturer’s instructions. Commercially available ELISA kits were used to determine plasma levels of interferon-inducible protein 10 (IP-10
or CXCL10) and D-dimer (Sekisui Diagnostics) and I-FABP
(Hycult Biotech) according to the manufacturer’s instructions. Duplicates of 20% of the samples were included in each
ELISA plate. The plasma kynurenine-to-tryptophan (KT) ratio
was determined using published techniques [17]. Glucose and
insulin were batch-analyzed on stored plasma. Fasting lipid
2 • OFID • Presti et al

profiles were batch-analyzed on stored serum. Insulin resistance was estimated by the homeostasis model assessment–insulin resistance (HOMA-IR) [18]. Participants were provided
with stool collection kits. In the substudy, colonic biopsies
were collected by flexible sigmoidoscopy at baseline and week
24 to assess tissue-specific effects related to immunologic outcomes, inflammation, bacterial translocation, and gut integrity. A lactulose mannitol (LM) test for gut permeability was
performed at baseline and week 26 [19, 20]. The methods used
for blood testing for inflammatory and metabolic biomarkers,
immunohistochemistry staining of the colonic biopsies,
microbiome analysis, symptom and dietary questionnaires, and
lactulose mannitol testing are provided in the Supplementary
Methods. Safety assessments were performed at weeks 6, 14, 26,
and 38.
Study Product

DuPont/Danisco manufactured Visbiome ES and matched placebo for Visbiome ES for Exegi Pharma (Rockville, MD, USA),
who supplied the product. Visbiome ES contains 1 strain of
Streptococcus thermophiles, 3 strains of Bifidobacteria, and 4 strains
of Lactobacilli in defined ratios. Each sachet contains at least 900
billion lyophilized lactic acid bacteria. For weeks 2–4, participants
were instructed to take 1 sachet orally daily. For weeks 4–26, participants were instructed to take 1 sachet orally twice daily.
Statistical Analysis

The primary outcome was change in sCD14 levels from baseline (average of entry and week 2) to week 26 (average of week
25 and week 26). Based on a prior study, a 0.07 log10 µg/Ll
sCD14 difference was associated with a 23% decreased odds
of a non-AIDS event or nonaccidental death at the pre-event
time point [21], suggesting it would be a clinically significant
reduction, and this guided the effect size for the study. With
45 participants per study arm, there was 90% power to detect
this 0.07 log10 µg/L between-arm difference assuming an SD of
0.09 log10 µg/L, a 5% type 1 error, and 20% of participants with
missing end points. Loss to follow-up in this study was higher
in the placebo arm, but despite this, with 42 Visbiome ES participants and 31 placebo participants, we still had 89.97% power
to detect this difference. The continuous secondary outcomes
assessed changes over the 24-week treatment period and the
12-week post-treatment period. Unlike the primary sCD14 outcome, secondary outcomes did not utilize averaging at baseline
and week 26.
For the subset of participants who completed paired colonic
biopsies, the primary outcome was change in CD4+ T cells
(median % positive staining) in colonic tissue over 24 weeks of
treatment. With 20 participants per study arm, there was 90%
power to detect a 20.1% between-arm difference in CD4+ T
cells assuming an SD of 16.4%, a 5% type 1 error, and 20% of
participants with missing end points.
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virus (SIV)–infected macaques [15]. Colonic CD4+ T cells
were reconstituted to near normal levels in the animals that
received ART and Visbiome compared with ART alone, and a
significantly greater number of antigen presenting cells could
be measured. Probiotic products have also been studied in the
setting of HIV infection, but with mixed results (reviewed in
[16]). Given its promise in animal models, in AIDS Clinical
Trials Group study A5350, we evaluated whether the probiotic
Visbiome Extra Strength (ES) reduced measures of systemic
inflammation in persons with well-controlled HIV on ART.
In a substudy (A5352s), we obtained colonic biopsies and performed immunohistochemistry to evaluate gut pathology. We
additionally performed lactulose mannitol testing to evaluate
functional gut permeability before and after Visbiome ES treatment. We hypothesized that Visbiome ES would be safe and repair intestinal pathology and reduce gut microbial translocation
and inflammation in PWH.

which used fold change. All statistical tests were 2-sided with
a nominal alpha level of .05 and no adjustment for multiple
testing.
RESULTS
Cohort Characteristics

Overall, 93 participants enrolled between April and
December 2016 and completed follow-up in September 2017
per protocol: 46 placebo, 47 Visbiome ES; 86% natal male sex;
55% White, 42% Black or African American, 20% Hispanic/
Latino ethinicity; median (Q1, Q3) age was 51 (45, 56) years,
BMI (Q1, Q3) was 27.1 (24.2, 30.7) kg/m2, CD4 count (Q1,
Q3) was 712 (542, 893) cells/mm3, and 99% had HIV-1 RNA
<40 copies/mL; 1 participant had 48 copies/mL (Figure 1).
Excluding 19 participants who did not complete study treatment and 1 virologic failure, 73 participants (31 placebo, 42
Visbiome ES) remained in the population. Of 42 participants

Assessed for eligibility (n = 121)
Enrollment
Excluded (n = 28)
Did not meet inclusion criteria (n = 17)
Declined to participate (n = 4)
Screening period expired (n = 7)
Randomized (n = 93)

Allocation
Allocated to placebo (n = 46)
Received placebo (n = 43)
Did not receive placebo (n = 3)
Withdrew before initiation (n = 2)
Lost to follow-up before initiation (n = 1)

Allocated to visbiome ES (n = 47)
Received visbiome ES (n = 47)

Lost to follow-up (n = 1)
Participant withdrew (n = 1)
Discontinued visbiome ES (n = 3)
Adverse event (n = 2)
Noncompliance (n = 1)

Follow-up

Lost to follow-up (n = 8)
Participant withdrew (n = 6)
Participant died (n = 1)
Other (n = 1)
Discontinued placebo (n = 4)
Adverse event (n = 1)
Noncompliance (n = 2)
Other (n = 1)

Analysis
Analyzed in per-protocol population
(n = 42)
Excluded due to virologic failure (n=1)

Analyzed in per-protocol population
(n = 31)

Figure 1. Trial flowchart. Abbreviation: ES, Extra Strength.
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To examine the biologic effects of Visbiome ES, we used
per-protocol analyses, limited to participants on treatment
through week 26, without confirmed virologic failure (2 consecutive ≥200 copies/mL of HIV-1 RNA) at or before week 26,
who had primary outcome data (sCD14 for main study outcomes and quantifiable intestinal CD4+ T cells for substudy
outcomes). Mean changes in main study outcomes were compared between arms using a 1-sample t test with equal variance. If data were highly skewed and log10 transformed, means
were exponentiated to estimate geometric mean fold changes
within arms and the percent difference in geometric mean fold
changes between arms. Due to the sample size in the substudy,
the Wilcoxon rank-sum test was used to compare treatment
arms. Participants who received any study product were included in the safety analysis, which compared the proportion
with adverse events between arms using the Fisher exact test.
Absolute change was used for all continuous outcomes except
for CD4+/CD8+ ratio and lactulose mannitol ratio (LMR),

enrolled into A5352s, 29 had paired biopsy specimens for
analysis. The median (Q1, Q3) age for the substudy perprotocol population was 50 (44, 56) years; 26 (90%) natal
male sex; baseline CD4 count (Q1, Q3) was 718 (601, 925)
cells/mm3 (Table 1).
Effect on Biomarkers

Table 1.

Effect on the Microbiome

No differences between groups or changes over the course of
the study were seen in the microbial diversity as measured by
Shannon diversity index nor richness as measured by the Chao1
Richness Index. Although not statistically significant, we detected an increase in both Lactobacillus and Bifidobacterium
in participants on Visbiome ES, which decreased to baseline
values after discontinuation of study product (Figure 3A, C).
Geometric mean fold differences from baseline to week 26 between the Visbiome ES and placebo groups were demonstrated
for Lactobacillus of +109.0% (95% CI, –62.6% to 1068.2%;
P = .39) and Bifidobacterium of +199.5% (95% CI, –63.7% to
2373.4%; P = .30), with variability among participants (Figure
3B, D). Of other microbial communities, Gammaproteobacteria

Baseline Characteristics of Main Study and Substudy Population
Main Study

Substudy

Overall (n = 93)

Visbiome ES
(n = 47)

Placebo (n = 46)

Overall (n = 29)

Visbiome ES
(n = 14)

Placebo (n = 15)

Age, y

51
(45, 56)

51
(47, 56)

52
(42, 56)

50
(44, 56)

50
(45, 56)

50
(42, 56)

Female sex

13 (14)

7 (15)

6 (13)

3 (10)

3 (21)

0 (0)

50 (55)
38 (42)

24 (53)
21 (47)

26 (57)
17 (37)

13 (45)
15 (52)

6 (43)
8 (57)

7 (47)
7 (47)

19
(20)

10
(21)

9
(20)

3
(10)

2
(14)

1
(7)

27
(24, 31)

27
(25, 31)

26
(24, 30)

27
(24, 29)

27
(26, 29)

26
(24, 28)

Current smoker

19
(21)

9
(19)

10
(23)

8
(28)

5
(36)

3
(20)

Current ethanol use

60
(66)

29
(62)

31
(70)

20
(69)

10
(71)

10
(67)

CD4 count, c/mm3

712 (542, 893)

702 (483, 866)

715 (546, 897)

718 (601, 925)

790 (601, 951)

712 (583, 897)

92
(99)

47
(100)

45
(98)

29
(100)

14
(100)

15
(100)

Characteristic

Race
White Black/African
American
Hispanic ethnicity
Body mass index, kg/m2

HIV RNA <40 copies/mL

Data are presented as median value (Q1, Q3) or No. (%).
Abbreviation: ES, Extra Strength.
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After 24 weeks of treatment, Visbiome ES did not significantly
reduce sCD14 compared with placebo; ∆ = –51.3 (95% CI, –246
to 143.9) µg/L (P = .60), after log10-transforming ∆ = –0.009
(95% CI, –0.043 to 0.025) log10 µg/L (P = .59) (Figure 2A). After
log10-transforming d-dimer values, the geometric mean fold
change from baseline to week 26 was 1.20 (95% CI, 0.97 to 1.50)
in the Visbiome ES arm, indicating a 20% relative increase to
the baseline level, and 28.4% (95% CI, –3.6% to 71.0%) greater
than the placebo (P = .09) (Figure 2B). Mean fold changes in
kynurenine-to-tryptophan (KT) ratio from baseline to week
26 were 1.04 (95% CI, 0.94 to 1.14) in the Visbiome ES arm
and 1.0 (95% CI, 0.94 to 1.05) in the placebo arm. There was
no evidence of a difference between the arms (∆ = 0.04; 95%
CI, –0.09 to 0.17; P = .51). Similar results were seen for IP-10
(Supplementary Table 1).
The mean changes in circulating CD4 cell counts from baseline to week 26 were 10 (95% CI, –32 to 52) cells/mm3 in the
Visbiome ES arm and 43 (95% CI, –3 to 88) cells/mm3 in the
placebo arm, with a difference in mean changes of –33 (95%
CI, –94 to 28) cells/mm3 between arms (P = .29) (Figure 2C).
Similarly, changes in CD4+/CD8+ ratio demonstrated no
difference between arms (P = .41), with mean fold changes
from baseline to week 26 of 1.03 (95% CI, 0.99 to 1.07) in the

Visbiome ES arm and 1.05 (95% CI, 1.01 to 1.09) in the placebo
arm. The difference in mean fold changes was –0.02 (95% CI,
–0.08 to 0.03) (Figure 2D).
We did not identify differences in changes for most peripheral blood mononuclear cell flow cellular markers analyzed,
except for the difference in percent expression of (CD8+)
CD28-CD57+ between arms in changes over 26 weeks, with a
mean increase over placebo of 2.28% (95% CI, 0.07% to 4.48%;
P = .043) (Supplementary Tables 2–4). Over the post-treatment
follow-up period (weeks 26–38), decreases in percent expression of (CD4+) CD28-CD57+ and (CD20-) CD27+CD38+ in the
Visbiome ES arm were statistically significantly greater from
placebo (P = .042 and P = .012, respectively); no other markers
were found to be statistically different in their changes over this
period.

Absolute soluble CD14, µg/L

A

Placebo

Placebo

Visbiome ES
Geometric mean (95% CI)

2000

1500

No. of participants
31
31
42
41

31
42
Baseline

25/26

500
400
300
200

100
Placebo
Visbiome ES

No. of participants
31
30
41
41

31
41
Baseline

38

26

C

D

Absolute CD4+ counts, cells/mm3
Placebo

Absolute CD4+/CD8+, ratio

Visbiome ES

Placebo

1200

Visbiome ES

1.50
Mean (95% CI)

Mean (95% CI)

38

Study week

Study week

1000
800
600

1.25
1.00
0.75

400
31
42

No. of participants
31
30
42
40
26

Baseline

38

0.50
Placebo
Visbiome ES

No. of participants
31
30
42
40

31
42
Baseline

Study week

26

38

Study week

Figure 2. Effects of Visbiome ES on biomarkers and cell counts. Mean values with 95% CIs shown in black bars, individual participants in blue circles (placebo) or red
triangles (Visbiome ES). Effects are shown at baseline, week 25/26, or week 38 for soluble CD14 (A), D-dimer (B), CD4+ T-cell count (C), or CD4+ T-cell/CD8+ T-cell ratio (D).
Abbreviation: ES, Extra Strength.

demonstrated statistically significantly different (P = .044) geometric mean fold changes from baseline to week 26 between
the Visbiome ES and placebo groups, with a percent difference
of –76.9% (95% CI, –94.4% to –4.0%) (Figure 3E). As seen in
Figure 3F, a distinguishable portion of individuals with a fold
change of Gammaproteobacteria <1 were in the Visbiome ES
group. No other changes or differences were seen in the rest of
the microbial communities analyzed.
Diet

Participants completed 24-hour recall [22] at baseline and
weeks 14, 26, and 38 using ASA24. We extracted the following Healthy Eating Index (HEI) measures [23]: added
sugar, sodium, dairy, fatty acid ratio, saturated fats, whole
fruit, total fruit, refined grains, whole grains, dark green
vegetables and beans, total vegetables, protein foods, seafood

and plant protein, and total score. Of all HEI measures, we
saw no differences between arms over the 24 weeks of active study treatment. During the post-treatment follow-up
period (weeks 26–38), participants reported differences in
saturated fat intake, with a mean increase of 2.51 (95% CI,
0.02 to 5.00; P = .049). No other notable changes or differences were seen in the rest of the HEI measures analyzed.
However, the diet of the participants was low for whole fruit,
whole grains, and dark green vegetables and beans, with a
total HEI score across the groups of 47, significantly lower
than the average American score of 59, and far from the ideal
score of 100 [23].
Effects on Metabolism

We did not observe any notable changes or differences between arms in fasting lipids (cholesterol, LDL, HDL, non-HDL
Assessing Probiotics in Treated PWH • OFID • 5
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Mean (95% CI)

2500

Placebo
Visbiome ES

Visbiome ES

700

3000

Placebo
Visbiome ES

Absolute d-dimer, ng/mL

B

Fold change in Lactobacillus at week 26, %
Placebo

50
20

Treatment group

Placebo

Visbiome ES

1000
Fold change

100
0.3

10
1
0.1

Placebo
Visbiome ES

0.01

No. of participants
22
29

Baseline

C

21
29

21
28

0.001

26
Study week

38

1e–4

D

Fold change in Bifodobacterium, %
Placebo

600

Treatment group

Placebo

Visbiome ES

1e4

200

1000

10

100

1
0.1

10
1
0.1

0.01
Placebo
Visbiome ES

Individual per-protocol participants (n=50)

Fold change in Bifodobacterium at week 26, %
1e5

Visbiome ES

Fold change

Geometric mean (95% CI)

Visbiome ES

Fold change in Lactobacillus, %
1e5
1e4

0.01

0.01

No. of participants
22
29

Baseline

E

21
29

21
28

0.001

26
Study week

38

1e–4

F

Fold change in Gammaproteobacteria, %
Placebo

60

Individual per-protocol participants (n=50)

Fold change in Gammaproteobacteria at week 26, %
1e5

Visbiome ES

Treatment group

Placebo

Visbiome ES

1e4

20

1000
100
Fold change

Geometric mean (95% CI)

B

0.3

10
1
0.1

0.01
Placebo
Visbiome ES

No. of participants
22
29

Baseline

0.01

21
29

21
28

0.001

26
Study week

38

1e–4

Individual per-protocol participants (n=50)

Figure 3. Effects on the microbiome. Geometric means with 95% CIs shown in black bars, individual participants in blue circles (placebo) or red triangles (Visbiome ES).
Effects are shown for Lactobacillus (A), Bifidobacterium (C), and Gammaproteobacteria (E). The fold change in each genus is shown for each participant for Lactobacillus (B),
Bifidobacterium (D), and Gammaproteobacteria (F). Participants in the placebo arm are shown in blue, and participants in the Visbiome ES arm are shown in red. Abbreviation:
ES, Extra Strength.
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Geometric mean (95% CI)

A

cholesterol or triglycerides), which were measured at baseline
and weeks 14 and 26. However, in exploratory analyses, we
identified a statistically significant treatment group difference
in fasting insulin and HOMA-IR fold changes from baseline to
week 26, with a geometric mean HOMA-IR difference of –39.7%
(95% CI, –59.0% to –11.3%; P = .011), although this was driven
by an increase in the placebo arm (Supplementary Table 5).

Overall, 25 participants (28%) reported at least 1 AE (8 [19%]
placebo and 17 [36%] Visbiome ES; P = .098). Examining
system organ classes where the difference in treatment arm proportions was >5%, 5 (11%) in Visbiome ES and 2 (5%) in placebo reported any gastrointestinal disorder; 4 (9%) in Visbiome
ES and 0 (0%) in placebo reported a musculoskeletal and connective tissue disorder; and 4 (9%) in Visbiome ES and 1 (2%)
in placebo reported a vascular disorder. Table 2 summarizes the
adverse events and grades. One participant in the placebo arm
discontinued study product due to an AE, while 2 discontinued
due to an AE in the Visbiome ES arm. Three participants assigned to placebo never initiated study product. There was 1
death in the placebo arm due to herpes encephalitis that was not
attributed to study drug.
Effect on Gastrointestinal Symptoms

Although gastrointestinal adverse events were more common
in the Visbiome ES arm, gastrointestinal symptom scores did
not reveal significant differences. At each visit, we performed
a symptom questionnaire assessing 5 symptoms (passing gas,
soft stools, excessive gas, hard stools, and watery stools) on a
scale of 0 (not present) to 10 (very severe). The mean changes in
the Visbiome ES arm ranged from –0.74 to –0.27, while in the
placebo arm they ranged from –0.29 to 1.10. For all 5 symptom
scores, the mean change in Visbiome ES was less than in the
Table 2.

Effect on the Gastrointestinal Tract

In the substudy with 42 participants enrolled, 29 with paired biopsy samples, there were no significant changes seen in CD4+,
IL-17, or MPO staining, measures of CD4+ T cells, Th17 cells,
and neutrophils. At baseline, the median % positive staining
for CD4+ T cells was 2.0% in the Visbiome ES arm and 2.1%
in the placebo arm. The median % CD4 decreased to 1.74%
in the Visbiome ES arm and 1.65% in the placebo arm, with
a median change of –0.21 for placebo and –0.03 for Visbiome
ES (P = .089) (Supplementary Figure 1A). IL-17 staining was
highly variable but demonstrated no significant change over 24
weeks (P = .65) (Supplementary Figure 1B). MPO minimally
decreased in placebo from 0.18 to 0.11, with a median change of
–0.04, while it increased in Visbiome ES from 0.14 to 0.18 for a
median change of 0.05 over 24 weeks (P = .081) (Supplementary
Figure 1C). Consistent with these findings, we demonstrated no
significant changes in gut permeability as measured by LMR,
although this may not have been the best measure of gut permeability [24]. At baseline, the overall median (Q1, Q3) ratio was
0.03 (0.02, 0.06). The median (Q1, Q3) fold change from baseline to week 26 was 0.66 (0.42, 1.35) in the Visbiome ES arm and
0.86 (0.74, 1.55) in the placebo arm. There was no evidence of
a difference between the arms (P = .35) (Supplementary Figure
1D). In addition, we saw no significant change in circulating
intestinal fatty acid binding protein (I-FABP), a marker of intestinal barrier dysfunction, which demonstrated a baseline mean
of 311 (95% CI, 186.7 to 518) pg/mL. I-FABP decreased in both
arms similarly over the course of the study to a mean of 211
(95% CI, 115 to 385) pg/mL [25].

Adverse Events
Visbiome ES (n = 47), No. (%)

a

Total

GI disorder

Placebo (n = 43), No. (%)

Overall

Grade 1–2

Grade ≥3

Overall

Grade 1–2

Grade ≥3

17 (36)

10 (22)

7 (15)

8 (19)

4 (9)

4(9)

5 (11)

4 (8)

1 (2)

2 (5)

1 (2)

1 (2)
1 (2)

Infections & infestations

4 (9)

3 (6)

1 (2)

2 (5)

1 (2)

Musculoskeletal

4 (9)

3 (6)

1 (2)

0

0

0

Metabolic/nutritional

1 (2)

1 (2)

0

1 (2)

1 (2)

0
0

Neoplasm

1 (2)

0

1 (2)

1 (2)

1 (2)

Renal/urinary

1 (2)

1 (2)

0

0

0

0

0

0

0

1 (2)

1 (2)

0

2 (4)

1 (2)

1(2)

0

0

0

0

0

0

1 (2)

1 (2)

0

Psychiatric
Respiratory/thoracic
Skin/soft tissue
General disorders

1 (2)

1 (2)

0

1 (2)

1 (2)

0

Injury/poisoning/procedural

2 (4)

1 (2)

1(2)

2 (5)

0

2 (5)

Abbreviations: AE, adverse event; ES, Extra Strength; GI, gastrointestinal.
a

Any AE: 17 (36%) vs 8 (19%); P = .098 by Fisher exact test.
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Safety of Study Product

placebo arm. Notably, the largest and only statistically significant (P = .002) difference was for passing gas, which was the
measure with the largest mean increase in placebo (1.10) and
the largest mean decrease in Visbiome ES (–0.74).

DISCUSSION
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Persistent microbial translocation and increased gastrointestinal permeability have been hypothesized to contribute to
chronic inflammation, morbidity, and mortality in PWH [8].
We performed a prospective, randomized, placebo-controlled
clinical trial to measure the effects of the probiotic Visbiome
ES on markers of inflammation, coagulation, the microbiome,
gastrointestinal structure and function, and metabolism. In a
cohort of virologically suppressed PWH with high CD4 counts
and minimal symptoms, we were unable to demonstrate a significant benefit of Visbiome ES administration.
Changes in several markers of systemic inflammation and
coagulation, including sCD14, d-dimer, KT ratio, and IP-10, or
in relevant measures of immune activation of lymphocytes and
monocytes were not different between arms (Supplementary
Data). There were also no significant effects on CD4+ T-cell
count or CD4/CD8 ratio in this cohort. Baseline sCD14 levels
were relatively low, and CD4+ T-cell counts and CD4/CD8
ratios (721 c/mm3 and 0.93, respectively) near normal. These
surrogate measures of immune function and inflammation indicated preserved or reconstituted immune function and presumably low systemic inflammation upon which the Visbiome
ES could render a meaningful benefit. Data from the START
trial suggest that PWH who initiate ART at CD4 counts >500 c/
mm3 and suppress HIV viremia have low measures of inflammation and very low incidence of non-AIDS comorbidities that
are historically linked to excess inflammation [26].
We considered whether variable engraftment of the probiotic might have affected results, but when comparing participants within the Visbiome ES arm with (n = 16) and without
(n = 13) increased Lactobacillus from baseline to week 26, no apparent difference in sCD14 changes was identified. One potential explanation for this finding is the high baseline CD4+ T-cell
counts with consistent virologic suppression and generally immunologically healthy population studied. A second possibility
may be poor dietary quality that did not facilitate engraftment
of the probiotic over time. Alternatively, the probiotic used may
not have been sufficient or appropriate to affect a meaningful
change in the microbiome composition of these individuals [27].
Finally, there is also a possibility that gut dysbiosis and inflammation are consequences rather than causes of systemic inflammation. Despite this, a recent study in SIV-infected nonhuman
primates suggested that altering the composition of the GI tract
microbiome does not accelerate untreated SIV disease [28], suggesting that the influence of the composition of the microbiome
may be more complex in its effects on HIV disease course.
As mentioned, dietary factors may have influenced the study
outcomes. Our study population had a persistently low-fiber
diet. The population of PWH living in the United States generally has a diet containing <20 g of fiber per day [29]. Recent
studies highlight that dietary fiber intake strongly influences

successful engraftment of probiotic bacteria, the duration of engraftment, and the effect on functional and clinical parameters
[30–32]. The nonhuman primate study of Visbiome that demonstrated colonic CD4+ cell restoration also provided the soluble prebiotic fiber inulin [15]. An unsuitable dietary nutrient
composition may prohibit engraftment or the ability of microbes to produce metabolites, such as short-chain fatty acids,
that improve health and anti-inflammatory outcomes [33–35].
We did not identify any apparent association within participants in the Visbiome ES arm between baseline total HEI and
fold changes in Lactobacillus or Bifidobacterium communities.
In conclusion, we present data from a well-powered, randomized, placebo-controlled intervention of probiotics in healthy
PWH on ART. The study product was generally safe and well
tolerated and did appear to shift the microbiome, but the study
did not demonstrate any significant benefit on inflammation or
gut permeability or translocation in this population, although
there may have been a benefit of preserved insulin sensitivity.
In an era in which PWH are aging and current ART is associated with an increase in weight gain and potential loss of insulin
sensitivity [35, 36], dietary interventions may be useful to ameliorate these consequences. A dietary intervention or combined
probiotic/prebiotic intervention, such as the prebiotic/probiotic
combination used in animal models [15], might result in better
engraftment and demonstrate biologic efficacy if utilized in a
population with more significant gastrointestinal pathology.
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